Management Team

Dr. Cameron Durrant

Founder, Chairman, President and CEO

Dr. Cameron Durrant is the Founder of PediatRx Inc., having conceived of and started the company based on his knowledge of the pediatric, hospital and oncology sectors and the unmet medical need that exists. Dr. Durrant is also the Executive Chairman of Anavex Life Sciences Corp. (AVXL:OB) a publicly traded drug development company with programs in central nervous systems disorders and cancer. He has deep experience in healthcare and pharmaceuticals and served most recently as Worldwide Vice President, Global Strategic Marketing, Infectious Diseases for Johnson & Johnson between March 2007 and December 2009. Dr. Durrant was a management consultant between January 2006 and February 2007, interim President and CEO of Spherics, Inc. in early 2006 and President and CEO of PediaMed Pharmaceuticals, a private pediatrics-focused specialty pharmaceutical company (which was sold to Connetics) between May 2003 and December 2005. Dr. Durrant has also held executive positions with Merck & Co, Glaxo Smith Kline PLC and Pharmacia Corporation (now part of Pfizer Inc.) where he was the Global Vice President for Infectious Diseases, before taking a senior staff position.

Dr. Durrant is a founding board member of Bexion Pharmaceuticals, a private oncology research and development company with therapeutics, diagnostic/imaging and drug delivery capabilities. Dr. Durrant is a former Chairman and Board member of Pressure Point Inc. (private medical device company); a former Board member of Topaz Pharmaceuticals (private pediatrics company); and a former Board member of PDS Biotechnology Corp (private nanotech oncology and infectious diseases R+D company). Dr. Durrant is currently an advisor to Pilgrim Software.

Dr. Durrant holds an MBA (Masters in Business Administration) from Henley Management College at Oxford and a MB and BCh (the UK equivalent to an American MD degree) from the Welsh National School of Medicine in Cardiff, U.K. as well as several post-graduate medical qualifications, including DRCOG (Diploma of the Royal College of Obstetricians and Gynaecologists), DipCH (Diploma of Clinical and Medical Hypnotherapy) and MRCGP (Member of the Royal College of General Practitioners).

He was a regional winner and national finalist for Ernst & Young’s Entrepreneur of the Year award in 2005. He has also been nominated by peers and colleagues as one of the 100 most inspiring people in the pharmaceutical industry in 2005, 2006, 2007 and 2010. He is a regular contributor to pharmaceutical and biotech industry issues and debates and a sought after public speaker.

David Tousley

Director, and Chief Financial & Administrative Officer

Mr. Tousley was appointed as secretary and treasurer of PediatRx Inc. on June 19, 2010. Mr. Tousley has over 25 years of senior-level experience in biotech, specialty pharmaceuticals and full-phase pharmaceutical companies. Since 2007, he has served as principal of Stratium Consulting Services, specializing in strategic and financial planning and management, corporate governance and business development.

From 2006 to 2007, he held the position of executive vice president and Chief Financial Officer of airPharma, LLC, and served in the same capacity for PediaMed Pharmaceuticals., Inc. between 2004 and 2006. In 1996, Mr. Tousley joined AVAX Technologies, Inc. as executive vice president, Chief Financial Officer and served in that position until 2001 when he became president and Chief Operating Officer, and acting Chief Executive Officer until his departure in 2003. Prior to AVAX, Mr. Tousley was the Vice President Finance and Administration for Pasteur Merieux Connaught (now Sanofi Pasteur) and was Chief Financial Officer for the U.S. operations, responsible for all finance and administration and customer account management. Mr. Tousley is a Certified Public Accountant in the state of New Jersey and holds an MBA in accounting from Rutgers Graduate School of Business and a B.A. in English from Rutgers College, both in New Jersey. Mr. Tousley is a director of Immunogenetix, Inc.